FDA OKs Asthma Drug for COPD
Links shared publicly online about this topic.
- 1,576total visits
FDA OKs Asthma Drug for COPD
View full resource at webmd.com
Tags: Asthma, Asthma Medication, COPD, Disease and Condition, Drug, FDA, Symbicort, Pulmonology
Most Recently Shared on November 25, 2009 at 4:09 pm By:
Just reading: FDA approves asthma drug to treat COPD http://bit.ly/5UxYFw
Which is better for COPD patients, albuterol inhaler or combivent inhaler?
healthtap.com — “Longer term studies show that both drugs are quick acting and relieve acute dyspnea/shortness of breath. It appears unlikely that either drug affects the natural history of asthma/COPD. Longer acting drugs called maintenance inhalers are associated with significant decreases in exacerbation (flares) of these diseases and may affect lung function longer term” View full resource at healthtap.com
Most Recently Shared on January 17, 2012 at 12:45 am By:
Which is better for COPD patients, albuterol inhaler or combivent inhaler? Two doctors from HealthTap recommend: http://t.co/okBWtssr #COPD
N30 Pharma Announces FDA Approval To Initiate Phase 1 Clinical Trial For First-in-Class Drug - QualityPoint Technologies
qualitypointtech.net — “N30 Pharmaceuticals, LLC announced the approval of its Investigational New Drug Application for N6022 by the U.S. Food and Drug Administration. N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR), has the potential to be an important new treatment for acute exacerbations of asthma, chronic obstructive pulmonary disease (COPD) and inflammatory bowel disease (IBD). N30 Pharma will now begin a first-in-man, Phase 1, dose escalation trial of N6022 in healthy subjects...” View full resource at qualitypointtech.net
Most Recently Shared on August 5, 2010 at 3:48 pm By:
N30 Pharma Announces FDA Approval To Initiate Phase 1 Clinical Trial For First-in-Class Drug: N30 Pharmaceuticals,... http://bit.ly/dlwMLG
Long-Acting Beta-Agonists (LABAs) - icyou health videos
icyou.com — “Long-Acting Beta-Agonists (LABAs), a class of medications used for the treatment of asthma and chronic obstructive pulmonary disease (COPD),...” View full resource at icyou.com
Most Recently Shared on July 28, 2010 at 9:00 pm By:
Tori Joseph - icyou.com Health Site
FDA: Long-Acting Beta-Agonists (meds used to treat asthma & COPD) now have new recommendations in their drug label http://ow.ly/2hXmY #LABAs
Asthma and COPD Inhalers That Contain Ozone-depleting CFCs to be Phased Out; Alternative Treatments Available
dld.bz — “The U.S. Food and Drug Administration today announced, in accordance with longstanding U.S. obligations under the Montreal Protocol on Substances that Deplete the Ozone Layer, seven metered-dose inhalers (MDI) used to treat asthma and chronic obstructive pulmonary disease (COPD) will be gradually removed from the U.S. marketplace. These inhalers contain ozone-depleting chlorofluorocarbons (CFCs), which are propellants that move medication out of the inhaler and into the lungs of patients. Altern” View full resource at dld.bz
Most Recently Shared on April 26, 2010 at 3:01 pm By:
Northside Allergy Allergist, Physician, Doctor, and Internist
Great tie into last week's earth day: FDA to remove asthma inhalers that deplete the Ozone layer.---> http://dld.bz/bvTh. Pls RT
Asthma and COPD Inhalers That Contain Ozone-depleting CFCs to be Phased Out; Alternative Treatments Available
fda.gov — “The U.S. Food and Drug Administration today announced, in accordance with longstanding U.S. obligations under the Montreal Protocol on Substances that Deplete the Ozone Layer, seven metered-dose inhalers (MDI) used to treat asthma and chronic obstructive pulmonary disease (COPD) will be gradually removed from the U.S. marketplace. These inhalers contain ozone-depleting chlorofluorocarbons (CFCs), which are propellants that move medication out of the inhaler and into the lungs of patients. Altern” View full resource at fda.gov
Most Recently Shared on April 13, 2010 at 8:40 pm By:
eyeonfda Health Lawyer and Pharma
FDA - Asthma and COPD Inhalers That Contain Ozone-depleting CFCs to be Phased Out http://ow.ly/1y46M
Mylan gets tentative FDA OK for generic Singulair - MarketWatch
marketwatch.com — “NEW YORK (MarketWatch) -- Mylan Inc. said Friday that it has received tentative approval from the U.S. Food and Drug Administration for its abbreviated new drug application for a generic version of Merck & Co.'s Singulair. Mylan said that the same strength of Singular, an allergy and asthma drug, had total U.S. sales of about $2.6 billion in the year ended March 31, according to IMS Health.” View full resource at marketwatch.com
Most Recently Shared on May 29, 2009 at 1:05 pm By:
eyeonfda Health Lawyer and Pharma
Mylan gets tentative FDA OK for generic Singulair http://bit.ly/9c5JI
Advertisement
